Relationship between leukemic cell retention of cytosine arabinoside triphosphate and the duration of remission in patients with acute non-lymphocytic leukemia.

No abstract is available for this paper.

• Publication year

  1985

• Venue

  European Journal of Cancer and Clinical Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0277-5379(85)90196-8PMID 4038655
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The pharmacokinetics of subcutaneous cytosine arabinoside in patients with acute myelogenous leukaemia.

  1981cited by this paper
• The Statistical Analysis of Failure Time Data

  1980cited by this paper
• Prediction of response to chemotherapy in acute myelocytic leukemia.

  1980cited by this paper
• Evaluation of in vitro predictive assays for acute myelocytic leukemia

  1980cited by this paper
• Correlation between leukemic cell retention of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and response to therapy.

  1979cited by this paper
• Treatment of acute nonlymphocytic leukemia: use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens.

  1979cited by this paper
• Remission induction in acute nonlymphocytic leukemia: comparison of a seven-day and ten-day infusion of cytosine arabinoside in combination with adriamycin.

  1979cited by this paper
• Failure of remission induction in acute myelocytic leukemia.

  1978cited by this paper
• Metabolism of 1-beta-D-arabinofuranosylcytosine in human leukemic cells.

  1977cited by this paper
• Metabolism of 1- β -d-Arabinofuranosylcytosine in Human Leukemic Cells

  1977cited by this paper
• Acute myelocytic leukemia.

  1976cited by this paper
• The metabolism of cytosine arabinoside as a predictive test for clinical response to the drug in acute myeloid leukaemia.

  1976cited by this paper
• Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group

  1976cited by this paper
• Uptake and phosphorylation of cytosine arabinoside by normal and leukemic human blood cells in vitro.

  1969cited by this paper
• STATISTICAL METHODS

  1967cited by this paper

• Oral cytarabine ocfosfate pharmacokinetics and assessment of leukocyte biomarkers in normal dogs

  2023cites this paper
• Consolidation in AML: Abundant opinion and much unknown.

  2021cites this paper
• Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers

  2021cites this paper
• Intracellular Pharmacokinetics of Pyrimidine Analogues used in Oncology and the Correlation with Drug Action

  2020cites this paper
• Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity

  2018cites this paper
• Clinical potential of elacytarabine in patients with acute myeloid leukemia

  2014cites this paper
• Cytidine Deaminase in Myeloprotective Gene Therapy

  2014cites this paper
• High-Dose Cytarabine (HD araC) in the Treatment of Leukemias: a Review

  2013cites this paper
• myelogenous leukemia using flow cytometry Detection of cytarabine resistance in patients with acute

  2011cites this paper
• Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126

  2011cites this paper
• Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.

  2009cites this paper
• Phospholipid/deoxycytidine analogue prodrugs for the treatment of cancer

  2009cites this paper
• Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia

  2009cites this paper
• Enhanced retention of cytosine arabinoside and its metabolites and synergistic cytotoxicity by sequential treatment with dipyridamole in L5178Y leukemia

  2008cites this paper
• The relevance of therapeutic drug monitoring in plasma and erythrocytes in anti-cancer drug treatment

  2004cites this paper
• [Clinical pharmacology of nucleoside analogues].

  2002cites this paper
• Citostáticos utilizados en los síndromes mieloproliferativos agudos. Mecanismos de acción y proyección de la farmacodinamia y la farmacocinética en la eficacia terapéutica y la toxicidad

  2001cites this paper
• Salvage therapy for refractory or relapsed acute lymphocytic leukemia.

  2001cites this paper
• Pharmacodynamics of cancer chemotherapy: childhood ALL as a model

  2001cites this paper
• Clinical Pharmacokinetics of Nucleoside Analogues

  2000cites this paper
• The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside‐based treatment regimens in acute myeloid leukaemia with a high proliferative activity

  2000cites this paper
• Successful modulation of high‐dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine

  2000cites this paper
• Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy

  1997cites this paper
• Correlation of Deoxycytidine Deaminase, Thymidine Kinase and Polymerase Alpha Activity and Deoxycytidine Deaminase Gene Expression In Vivo with Clinical Response to TAD-9+GM-CSF Induction Therapy in Acute Myeloid Leukemia

  1997cites this paper
• Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma.

  1996cites this paper
• [Detection of the resistance to Ara-C blast cells in acute myeloid leukemia using flow cytometry].

  1995cites this paper
• Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukemia.

  1995cites this paper
• New targets for pyrimidine antimetabolites for the treatment of solid tumours

  1994cites this paper
• New targets for pyrimidine antimetabolites in the treatment of solid tumours

  1994cites this paper
• Detection of cytarabine resistance in patients with acute myelogenous leukemia using flow cytometry.

  1994cites this paper
• Therapeutic drug monitoring in cancer management.

  1993cites this paper
• TherapeuticDrugMonitoring in CancerManagement

  1993cites this paper
• Long-term outcome of patients with acute myelogenous leukemia: the role of maintenance therapy, consolidation therapy and the predictive value of two in vitro assays.

  1993cites this paper
• Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia

  1993cites this paper
• 第12回日本臨床薬理学会記録 Ara-C の作用増強因子の検討

  1992cites this paper
• Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine.

  1991cites this paper
• Determinants of response and prediction of response to chemotherapy in acute myelogenous leukemia.

  1991cites this paper
• Enzyme Target Chemotherapy

  1991cites this paper
• Cytarabine and neurologic toxicity.

  1991cites this paper
• Fludarabine: A Review

  1991cites this paper
• Modulation of cytotoxic drug activity by dipyridamole.

  1990cites this paper
• Pharmacokinetics and Pharmacodynamics of Anticancer Agents: Contributions to the Therapy of Childhood Cancer

  1990cites this paper
• Metabolism of pyrimidine analogues and their nucleosides.

  1990cites this paper
• Rationales for a pharmacologically optimized treatment of acute nonlymphocytic leukemia with cytosine arabinoside.

  1990cites this paper
• Enhancement of 5-fluorouracil's anticancer activity by dipyridamole.

  1989cites this paper
• Clinical pharmacology of cancer chemotherapy in children.

  1989cites this paper
• Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia.

  1988cites this paper
• Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.

  1987cites this paper
• Pharmacokinetic parameters of 1-beta-D-arabinofuranosylcytosine (ara-C) and their relationship to intracellular metabolism of ara-C, toxicity, and response of patients with acute nonlymphocytic leukemia treated with conventional and high-dose ara-C.

  1987cites this paper
• Saturation of 1-β-d-Arabinofuranosylcytosine 5′-Triphosphate Accumulation in Leukemia Cells during High-Dose 1-β-d-Arabinofuranosylcytosine Therapy

  1987cites this paper
• Studies of ara-C metabolism in acute leukemia.

  1987cites this paper
• Cytosine arabinoside in the treatment of T-cell acute lymphoblastic leukemia.

  1987cites this paper
• Therapeutic Drug Monitoring in Oncology

  1987cites this paper
• Degradation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human leukemic myeloblasts and lymphoblasts.

  1987cites this paper
• Treatment of adult acute non-lymphoblastic leukemia: a computer-aided analysis.

  1987cites this paper
• Predictors of response of acute nonlymphocytic leukemia.

  1986cites this paper
• 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma.

  1986cites this paper
• 9-β-D-Arabinofuranosyl-2-fluoroadenine 5′-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma

  1986cites this paper
• Predictors of Response of Acute Nonlymphocytic Leukemia

  1986cites this paper
• Metabolism of ara-C by blast cells from patients with ANLL.

  1986cites this paper
• Cellular Heterogeneity of Human Tumors

  1985cites this paper
• 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response.

  1985cites this paper
• Remission Duration in Acute Nonlymphocytic Leukemia: Practical and Theoretical Considerations

  1984cites this paper